An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...

Speaking at the reopening of the Thailand office of Novo Nordisk, a leading global healthcare company, Mr Annan highlighted how the company is driven not only by pharmaceutical excellence but also ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...